Preclinical and clinical studies on HIF-1-targeting therapies have resulted in encouraging data for a number of different types of cancer15–17, but resultant therapies for brain tumors have so far proved elusive14,15,18,19. This evidence concerns the gene HIF1A and brain neoplasm.